International Medication Systems (UK) Ltd

208 Bath Road, Slough, Berkshire, SL1 3WE
Telephone: +44 (0)1753 534 655
Medical Information Direct Line: +44 (0)1753 447 690
Medical Information e-mail: medicalinformationuk@ucb.com
Customer Care direct line: +44 (0)800 953 0183
Medical Information Fax: +44 (0)1753 447 647

Summary of Product Characteristics last updated on the eMC: 07/04/2010
SPC Naloxone Hydrochloride Injection, Minijet.

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 07/04/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Feb-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Please note that we need to make a minor change to the EMC SPC.

The approval date should be February 2010.

Updated on 03/12/2009 and displayed until 07/04/2010
Reasons for adding or updating:
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   01-Nov-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company


In section  4.6 – Use during pregnancy and lactation  to add “Naloxone rapidly crosses the placental barrier so that some therapeutic effect may be anticipated in the neonate”


In section 4.8 – Undesirable Effects to add "violent behaviour as a symptom of abrupt reversal of narcotic depression and the rare occurrence of seizure from the administration of Naloxone"
Updated on 04/09/2007 and displayed until 03/12/2009
Reasons for adding or updating:
  • Change to section 6. 3 - Shelf Life
Date of revision of text on the SPC:   07/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Shelf-life increased from 2-3 years.
Updated on 24/11/2005 and displayed until 04/09/2007
Reasons for adding or updating:
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 3 - pharmaceutical form
  • Change to section 6.1 - List of Excipients
  • Change to section 6. 4 - Special Precautions for Storage
Updated on 03/10/2003 and displayed until 24/11/2005
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 28/06/2001 and displayed until 03/10/2003
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
   naloxone hydrochloride dihydrate